Skip to content
Medical Health Aged Care

De-escalation VR training for behavioural emergencies set to revolutionise dementia education

Dementia Australia 3 mins read

Dementia Australia has today launched D-Esc, a new innovative virtual reality (VR) training workshop for de-escalating a behavioural emergency in a care setting.               

D-Esc provides an immersive simulation, designed for frontline and health care professionals, to adopt an interactive approach to de-escalation training. Participants will build empathy and understanding towards people with dementia, with the aim to reduce the use of restrictive practices and the number and severity of dangerous incidents in care.

Dementia Australia Executive Director Services, Advocacy and Research Dr Kaele Stokes said this new workshop provides training which is integral to the safety and professional development of the workforce and to improving the care of people living with dementia.

“Behavioural emergencies and occupational violence in aged care are time-critical emergencies,” said Dr Stokes.

“We know that dementia can change people’s behaviour. People living with dementia may feel anxious, fearful, distressed, confused. They may also be in pain or disorientated.

“Sometimes the way they are experiencing a situation may mean a person is unable to communicate how they feel or what they are experiencing in the familiar ways.

“Additionally, the way a care worker communicates with people living with dementia is vital. Communication is not just talking.

“Gestures, movement and facial expressions can all convey meaning. Body language and physical contact become significant when speech is difficult for a person with dementia.

“Course participants will build their empathy, increase their understanding of dementia and skills in communication, recognising emotional and physical signs of escalation and how to reduce the risk of harm for both the person with dementia, other residents, visitors and staff.

“D-Esc leverages technology to build participants’ confidence and capability to assess and respond effectively to changed behaviours safely.”

Dementia Australia Dementia Advocate Phil Hazell lives with younger onset dementia. Mr Hazell believes that training like this is important for promoting understanding and awareness around dementia.

“I like to know that I am understood. It is important that people comprehend what dementia is and how it can affect people differently,” said Mr Hazell.

“Training can help workers to understand, approach and help people living with dementia, without making assumptions.”

Launch events for D-Esc to the aged care sector are scheduled across Sydney, Melbourne, and Adelaide where guests can experience demonstrations.

The D-Esc workshops are designed for frontline health and aged care workers across residential, home and community care, primary and acute care and disability care. Workshop delivery is an in person 3-hour workshop, with up to 15 participants.

D-Esc is a fully funded workshop until 30 June 2025, available to 6,500 eligible participants. To confirm the eligibility of your staff please visit dementia.org.au/d-esc or contact development@dementia.org.au.

D-Esc was developed with the Applied Artificial Intelligence Institute (A²I²), Deakin University.

D-Esc is a Dementia Australia program created with support from The Rosemary Norman Foundation, Fitzpatrick Sykes Family Foundation, Navarra Care Foundation and Australian Communities Foundation through HDR Australia Fund. With the support of Dementia Training Australia and the Australian Government, the D-Esc workshop is free for 6,500 eligible participants until 30 June 2025.

Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

-Ends-

Media contacts:

Catherine McCarthy, Media & Communications Advisor, Catherine.Mccarthy@dementia.org.au, 0466 796 201

Gabrielle Prabhu, Media & Communications Manager, Gabrielle.Prabhu@dementia.org.au, 0447 253 583

 

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.

Media

More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.